Advertisement
Radiopharm Theranostics Limited

Radiopharm Theranostics Limited (RAD.AX) Stock Competitors & Peer Comparison

See (RAD.AX) competitors and their performances in Stock Market.

RAD.AXASX
HealthcareBiotechnology
$0.02
$0.001(5.000%)
Australian Market is Open · 14:57
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
RAD.AXA$0.02-5.00%44.9M-0.95-A$0.02N/A
CSL.AXA$101.75+3.92%47.6B11.50A$8.65+4.28%
TLX.AXA$13.48+1.28%4.5B-446.33-A$0.03N/A
MSB.AXA$2.02-1.71%2.6B-20.40-A$0.10N/A
NEU.AXA$13.23-3.08%1.7B58.39A$0.23N/A
OPT.AXA$0.60+0.00%820.8M-60.00-A$0.01N/A
CU6.AXA$2.09-7.11%801.9M-7.68-A$0.28N/A
PYC.AXA$1.17-5.67%696.7M-14.94-A$0.08N/A
RAC.AXA$2.41-10.74%497.3M-51.00-A$0.05N/A
CUV.AXA$8.74-4.27%446.6M13.84A$0.64+0.56%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

RAD.AX vs CSL.AX Comparison June 2026

RAD.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RAD.AX stands at 44.9M. In comparison, CSL.AX has a market cap of 47.6B. Regarding current trading prices, RAD.AX is priced at A$0.02, while CSL.AX trades at A$101.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RAD.AX currently has a P/E ratio of -0.95, whereas CSL.AX's P/E ratio is 11.50. In terms of profitability, RAD.AX's ROE is -0.93%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, RAD.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for RAD.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions